Nordic Nanovector signs global clinical and commercial agreement with ITM for the supply of no-carrier-added Lutetium-177

Booking.com

Oslo, Norway, 7 October 2019

Nordic Nanovector ASA (OSE: NANO) announces that it has signed a long-term global supply agreement with a subsidiary of ITM Isotopen Technologien München AG (ITM),  Isotope Technologies Garching GmbH (ITG) to ensure the supply of high quality, no-carrier-added (n.c.a.) Lutetium-177, a key component of Betalutin® (177Lu-lilotomab-satetraxetan) for R&D, clinical and commercial uses.

ITM, a biotechnology and radiopharmaceutical group of companies and world-leader in the development and production of radiopharmaceuticals and radionuclides for the targeted

Booking.com

Source: Nordic Nanovector signs global clinical and commercial agreement with ITM for the supply of no-carrier-added Lutetium-177

Booking.com

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.